ライフサイエンスコーパス: definitive therapy

1 tive) with Loa loa both before and following definitive therapy.

2 nt reigns, often to the point of withholding definitive therapy.

3 gulatory cytokines that normalized following definitive therapy.

4 if this association is true for empiric and definitive therapy.

5 ould be sought at an early stage to initiate definitive therapy.

6 ation therapy as the initial and potentially definitive therapy.

7 in vitro and would be particularly useful as definitive therapy.

8 have failed or may serve as a bridge to more definitive therapy.

9 ) or metastases or death (14 articles) after definitive therapy.

10 and transplantation of the liver is the only definitive therapy.

11 tibiotic agents, should they be required for definitive therapy.

12 e and in trying to discern metastasis before definitive therapy.

13 (+)) and do not (BCR (-)) have BCR following definitive therapy.

14 cholecystectomy should be considered as the definitive therapy.

15 ich may decrease the morbidity of subsequent definitive therapy.

16 n of mature new bone appeared to be the only definitive therapy.

17 Two patients died without an attempt at definitive therapy.

18 % of patients were seen for consideration of definitive therapy.

19 cing or excision of ectopic masses may offer definitive therapy.

20 mporize symptoms and function as a bridge to definitive therapy.

21 s, regardless of the beta-lactam selected as definitive therapy.

22 ll carcinoma (approximately 1%-2%) following definitive therapy.

23 nts with Zenker diverticulum did not undergo definitive therapy.

24 or during transportation prior to receiving definitive therapy.

25 clinicians in selection of both empiric and definitive therapies.

26 erventions, such as sequences of empiric and definitive therapies.

27 Despite definitive therapy, 2% to 56% of men with localized dise

28 l was 76% of 99 patients who received TUR as definitive therapy (57% with bladder preserved) compared

29 fidence interval [CI], .29-4.40; P = .84) or definitive therapy (adjusted HR, 0.76; 95% CI, .28-2.07;

30 2 to 0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% CI, 1.51 to 1

31 Progress in diagnosis, management and definitive therapies affects the natural course and henc

32 llowed by local definitive therapy, or local definitive therapy alone for cisplatin-ineligible patien

33 in whom carefully performed FSS may serve as definitive therapy and in whom adjuvant RT may not be ne

34 ed metastasis who are candidates for initial definitive therapy and patients with suspected recurrenc

35 enter study included PCa patients with prior definitive therapy and suspected PCa recurrence.

36 Vancomycin was the most commonly used definitive therapy, and 40 patients (78.4%) received mul

37 tus and stage at presentation, employment of definitive therapy, and all-cause mortality was assessed

38 ad received radical prostatectomy as initial definitive therapy, and baseline median PSA level was 0.

39 firmed adenocarcinoma of the prostate, prior definitive therapy, and BCR (defined as a prostate-speci

40 blood cultures within 72 h after initiating definitive therapy, and change in therapy due to perceiv

41 surveillance and definition of a trigger for definitive therapy, and prognostication of time to hormo

42 od loss has been controlled but before other definitive therapies are available.

43 Despite significant progress, definitive therapies are often lacking.

44 nces in medical practice have occurred while definitive therapies based on an improved knowledge of d

45 Patients then received definitive therapy based on institutional preferences.

46 beta-lactams are superior to vancomycin for definitive therapy but not for empiric treatment.

47 Immediate delivery is the only definitive therapy, but many maternal complications can

48 : the empirical therapy cohort (ETC) and the definitive therapy cohort (DTC).

49 omycin but may be switched to daptomycin for definitive therapy, especially if treatment failure is s

50 sfunction were often dissuaded from pursuing definitive therapy, even though most patients died from

51 utations remains poorly investigated, and no definitive therapies exist for Wolfram syndrome 1.

52 antation and solid organ transplantation are definitive therapies for several otherwise fatal conditi

53 The role of PCI as definitive therapy for allograft coronary disease (ACD)

54 mediary in cases of treatment failure, or as definitive therapy for benign prostatic hyperplasia and

55 c stem cell transplantation remains the only definitive therapy for LAD; however, the degree of donor

56 Following definitive therapy for localized disease with radical pr

57 ce of prostate carcinoma was suspected after definitive therapy for localized disease, (b) bone scans

58 Lung transplantation is the only definitive therapy for many forms of end-stage lung dise

59 l setting of biochemical failure after prior definitive therapy for primary cancer.

60 ccurate evaluation of local recurrence after definitive therapy for prostate cancer.

61 Heart transplantation remains the most definitive therapy for qualified candidates with end-sta

62 n; however, independent of primary location, definitive therapy for teratomas is complete surgical re

63 teremic or having received vancomycin as the definitive therapy for their infections.

64 Liver transplantation represents the only definitive therapy for this disease and has been perform

65 as a bridge to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liv

66 In pursuit of definitive therapy for XLA, we tested ex vivo gene thera

67 s the potential of this strategy as a future definitive therapy for XLA.

68 These encouraging conversion rates to definitive therapy, highlight the potential of chemoimmu

69 infections, beta-lactams are recommended for definitive therapy; however, the comparative effectivene

70 c testing can result in significant delay in definitive therapies in patients with severe pancytopeni

71 onade in 91 cases (99%) and was the only and definitive therapy in 82% of the cases.

72 Shunting was undertaken as definitive therapy in all.

73 mponade is recommended only as a "bridge" to definitive therapy in patients with cirrhosis and massiv

74 le of induction chemotherapy (IC) in guiding definitive therapy in patients with SNUC.

75 ith corticosteroids and anticonvulsants, and definitive therapy in the form of whole-brain radiation

76 ue obtained by means of biopsy or as part of definitive therapy (including a loop electrosurgical exc

77 bitory concentration </= 8 mug/mL), cefepime definitive therapy is inferior to carbapenem therapy in

78 BCR post definitive therapy is often associated with disease prog

79 cantly in 30%-60% of NSCLC patients for whom definitive therapy is planned.

80 Chemoradiation as definitive therapy is the preferred primary therapy for

81 patient autonomy, and despite the absence of definitive therapy, many newly diagnosed individuals are

82 rgical therapies for recurrent disease after definitive therapy of anal carcinoma, colorectal cancer,

83 beta-lactams with vancomycin for empiric and definitive therapy of MSSA bloodstream infections among

84 st patients and families in the selection of definitive therapies or palliation.

85 es durable tumor control when used either as definitive therapy or as a postoperative adjuvant therap

86 d neoadjuvant chemotherapy followed by local definitive therapy, or local definitive therapy alone fo

87 prompt initiation of supportive measures and definitive therapy, outcomes can be improved.

88 ess commonly referred than B(+) patients for definitive therapies (P < 0.01).

89 Conversely, definitive therapy provided significant benefit by impro

90 ms, using third-generation cephalosporins as definitive therapy remained associated with this adverse

91 mization, 4 of 9 (44%) patients who received definitive therapy remained on trial-none of whom had ev

92 e allograft vascular bed, the only currently definitive therapy requires re-transplantation.

93 rior prostatectomy, radiation therapy, or no definitive therapy, respectively).

94 Patients should receive beta-lactams for definitive therapy, specifically antistaphylococcal peni

95 ful strategy to prevent morbidities before a definitive therapy, such as hematopoietic stem-cell tran

96 y, depressed men were less likely to undergo definitive therapy (surgery or radiation) across all ris

97 or-chosen chemotherapy, region, and previous definitive therapy, to tislelizumab 200 mg or placebo in

98 puted tomographic (CT) technology, and rapid definitive therapy, trauma to the aorta continues to be

99 The median time since definitive therapy was 7 y (interquartile range [IQR], 4

100 Definitive therapy was defined as starting treatment bet

101 Prior definitive therapy was radical prostatectomy (n = 24, 96

102 Patients who received cefepime (n = 17) as definitive therapy were more likely to have a clinical f

103 However, patients who received definitive therapy with a beta-lactam had 35% lower mort

104 tients with ESBL bacteremia who all received definitive therapy with a carbapenem.

105 Physicians might consider definitive therapy with cefazolin for these infections.

106 This study compared definitive therapy with cefazolin vs nafcillin or oxacil

107 blood culture positive for MSSA and received definitive therapy with cefazolin, nafcillin, or oxacill

108 3167 patients, 1163 (37%) patients received definitive therapy with cefazolin.

109 CR) post-therapy will potentially complement definitive therapy with either neo- or adjuvant therapy

110 , improved outcomes have been reported after definitive therapy with hematopoietic stem cell transpla

111 ome women with Graves disease opt to receive definitive therapy with RAI or surgery prior to becoming

112 and nonmetastatic prostate cancer underwent definitive therapy with surgery or radiation therapy wit

113 No recurrences were observed after definitive therapy, with follow-up of 4 +/- 4 years.